The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...

Please provide your email address to receive an email when new articles are posted on . An 84-year-old woman presented to the Tufts Medical Center emergency department with a chief complaint of ...

The US Food and Drug Administration has granted breakthrough therapy designation to Oculis’ neuroprotective candidate ...

A nationwide cohort study of more than 4 million adults showed that people with allergic diseases were nearly one third more likely to develop optic neuritis than those without such conditions, with ...

Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded data analysis from Phase 3 Stage 1 DIAMOND program for OCS-01 ...

"Patients with anti-AQP4-Ab may basically need long-term relapse prevention, because they surely experience much higher relapse activity, with much worse neurological disturbance…In MOGAD patients, ...